Key facts
- It has raised $41.2M; the latest was Early Stage VC ($27.5M) in Nov 2025.
- Notable investors include Qiming Venture Partners, YuanBio Venture Capital, Shenzhen Nanshan Strategic Emerging Industry Investment, Boyu Capital, BioTrack Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Oukojian
- ·The full record, as it builds
Funding rounds
No funding rounds for Oukojian are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oukojian
Operator of ophthalmic biopharmaceutical therapies intended for innovative treatment of fundus diseases. The company provides a platform encompassing early-stage drug target discovery, macromolecular drug design, preclinical validation, and commercialization strategies, featuring advanced biochemical engineering, scalable R&D infrastructure, and integration of global expertise, enabling ophthalmology markets in China and worldwide to address unmet clinical needs, improve patient outcomes, and accelerate the adoption of next-generation therapeutic solutions.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2022
- Website
- oculgen.com/
- Ownership
- Privately Held (backing)
Oukojian doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oukojian shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oukojian in its N-PORT filings yet. We sweep new filings monthly.